The FDA approved BIOTRONIK’s Estella and Effecta pacemakers, as well as Vp (ventricular pace) Suppression feature in the Evia line. Evia and Estella pacemakers are compatible with BIOTRONIK’s Home Monitoring technology for reporting device readings directly to the physician.
From the press release:
The Evia family combines the industry’s smallest wireless remote monitoring pacemakers with a decade of longevity. This advancement increases the intervals between necessary device replacement procedures, which could potentially reduce the risk associated with replacements—a risk demonstrated in the recently published REPLACE study .
The Evia family significantly expands BIOTRONIK’s spectrum of innovative treatment options to maximize intrinsic conduction, thus reducing unnecessary right ventricular pacing. Ventricular pace suppression, known as Vp Suppression, is a new, highly sophisticated algorithm that can promote innate conduction by enabling the pacemaker to stimulate the heart muscle only when appropriate.
Evia also features BIOTRONIK’s proprietary Closed Loop Stimulation (CLS), a unique pacing solution with a proven, physiological rate regulation algorithm that is the most advanced on the market. CLS is the only rate-response technology to receive FDA labeling as responding to physical and acute mental stress.
Press release: BIOTRONIK Receives FDA Approval for Expansion of the Premium Evia Pacemaker Portfolio
Product page: Estella; Evia; Effecta